Sunesis Pharmaceuticals (NASDAQ: SNSS) announced that the first patient has been treated in an investigator-sponsored pilot study of vosaroxin and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE